From STAT’s Elaine Chen: GLP-1 drugs seem to be a source of contention among the people in President-elect Trump’s circle.

Earlier this week, Elon Musk tweeted: “Nothing would do more to improve the health, lifespan and quality of life for Americans than making GLP inhibitors super low cost to the public.” It’s a sentiment he’s expressed several times before. (The drugs are not actually inhibitors; they’re agonists.)

Then, Calley Means, an entrepreneur who was critical in birthing the MAHA movement, responded, saying that Musk’s post “misses the spiritual crisis we are facing.” Means said the drugs should only be a small part of the effort to address chronic disease rates, and he claimed that Novo Nordisk “has been able to pay US regulators, media, and lawmakers to force this drug down our throats as the only option.”

It’s yet to be seen how the Trump administration will actually approach potential policies around GLP-1 drugs. Axios recently reported that the CEO of Eli Lilly, maker of Mounjaro and Zepbound, went to Mar-a-Lago to meet with Trump.

And what does RFK Jr., Trump’s pick for HHS secretary and nominal leader of the MAHA movement, think of GLP-1s? Before the election, he issued a post on X that was quite critical of the drugs, noting that they have potential side effects and suggesting that there should be a greater priority on addressing the root causes of obesity. “We should consider replanting the kitchen garden before sending more money to Denmark,” he said, referring to Novo Nordisk’s headquarters.

Lately, though, it seems his tone on GLP-1s has softened. When asked very briefly by CNBC’s Jim Cramer about his thoughts on the treatments, he said that making lifestyle changes is most important, but GLP-1 drugs “have a place.”

In general, cracks have started to form in the MAHA coalition as the Trump administration announces nominations. My colleague Isa Cueto dug into that here.